Affordable Access

deepdyve-link
Publisher Website

Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor.

Authors
  • McCaffery, Ian
  • Tudor, Yanyan
  • Deng, Hongjie
  • Tang, Rui
  • Suzuki, Samuel
  • Badola, Sunita
  • Kindler, Hedy L
  • Fuchs, Charles S
  • Loh, Elwyn
  • Patterson, Scott D
  • Chen, Li
  • Gansert, Jennifer L
Type
Published Article
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Publication Date
Aug 01, 2013
Volume
19
Issue
15
Pages
4282–4289
Identifiers
DOI: 10.1158/1078-0432.CCR-12-1840
PMID: 23741071
Source
Medline
License
Unknown

Abstract

Baseline circulating factors of the IGF axis may predict OS benefit from ganitumab plus gemcitabine in metastatic pancreatic adenocarcinoma.

Report this publication

Statistics

Seen <100 times